Proteomics International Laboratories Ltdの主要な財務諸表は何ですか?
最新の財務諸表(Form-10K)によると、Proteomics International Laboratories Ltdの総資産は$14で、純損失は$-8です。
PIQLFの主要な財務比率は何ですか?
Proteomics International Laboratories Ltdの流動比率は14、純利益率は-266.66、1株当たり売上高は$0.02です。
Proteomics International Laboratories Ltdの収益はセグメントまたは地域別にどのように分けられていますか?
Proteomics International Laboratories Ltd の最大収益セグメントは Analytical Services で、最新の利益発表における収益は 876,890 です。地域別に見ると、Australia and New Zealand が Proteomics International Laboratories Ltd の主要市場であり、収益は 782,649 です。
Proteomics International Laboratories Ltdは収益を上げていますか?
いいえ、最新の財務諸表によると、Proteomics International Laboratories Ltdの純損失は$-8です。
Proteomics International Laboratories Ltdに負債はありますか?
はい、Proteomics International Laboratories Ltdの負債は1です。
Proteomics International Laboratories Ltdの発行済株式数は何株ですか?
Proteomics International Laboratories Ltdの総発行済株式数は163.52株です。
主要データ
前終値
$0.26
始値
--
当日レンジ
-
52週レンジ
$0.26 - $0.31
取引高
--
平均取引高
0
配当利回り
--
1株当たり利益(TTM)
-0.04
時価総額
$42.9M
PIQLFとは何ですか?
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bioanalytical services. The company specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. The company focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.